Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, with more than
700,000 new cases in the world every year. China has the highest incidence and death rate of
HCC in the world, accounting for 55% of the world's annual incidence and 45% of the world's
annual deaths. At present, surgical resection is still one of the most effective treatments
for HCC. However, the recurrence rate of tumor after hepatectomy is still very high, and the
recurrence rate of 5 years is 60~70%. Especially in patients with high-risk recurrence
factors, without intervention, the cumulative recurrence rate in the first year was about
50%, about 60% in the second year, about 70% in the third year, and about 80% in the fifth
year. Tumor recurrence is an important bottleneck that hinders the long-term survival of
patients. Therefore, there is an urgent need for effective adjuvant therapy to reduce the
postoperative recurrence rate of patients with HCC, especially high-risk patients. However,
there is still a lack of standard protocols for postoperative adjuvant therapy for HCC. Here
investigators intend to explore the safety and efficacy of Donafinib Combined With Anti-PD-1
Antibody as postoperative adjuvant therapy for HCC patients with high risks of recurrence.